Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:LRMR NASDAQ:ONCO NASDAQ:VALN NASDAQ:VERV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeLRMRLarimar Therapeutics$3.38-33.6%$3.89$1.61▼$9.50$279.80M0.911.31 million shs23.76 million shsONCOOnconetix$3.21-5.3%$3.11$2.45▼$552.50$4.98M3.36358,904 shs159,491 shsVALNValneva$10.95+12.8%$9.08$3.62▼$12.25$940.90M1.7969,788 shs106,338 shsVERVVerve Therapeutics$11.13$11.13$2.86▼$11.40$992.13M2.233.94 million shsN/AThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceLRMRLarimar Therapeutics0.00%+21.19%+40.61%+76.12%-22.53%ONCOOnconetix0.00%+14.14%+15.70%-28.93%-99.33%VALNValneva0.00%-4.62%+9.72%+71.25%+56.36%VERVVerve Therapeutics0.00%0.00%0.00%-0.89%+123.49%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeLRMRLarimar Therapeutics$3.38-33.6%$3.89$1.61▼$9.50$279.80M0.911.31 million shs23.76 million shsONCOOnconetix$3.21-5.3%$3.11$2.45▼$552.50$4.98M3.36358,904 shs159,491 shsVALNValneva$10.95+12.8%$9.08$3.62▼$12.25$940.90M1.7969,788 shs106,338 shsVERVVerve Therapeutics$11.13$11.13$2.86▼$11.40$992.13M2.233.94 million shsN/AThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceLRMRLarimar Therapeutics0.00%+21.19%+40.61%+76.12%-22.53%ONCOOnconetix0.00%+14.14%+15.70%-28.93%-99.33%VALNValneva0.00%-4.62%+9.72%+71.25%+56.36%VERVVerve Therapeutics0.00%0.00%0.00%-0.89%+123.49%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceLRMRLarimar Therapeutics 3.00Buy$18.43445.22% UpsideONCOOnconetix 0.00N/AN/AN/AVALNValneva 3.00Buy$15.0036.99% UpsideVERVVerve Therapeutics 2.33Hold$14.5730.92% UpsideCurrent Analyst Ratings BreakdownLatest ONCO, VERV, LRMR, and VALN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/8/2025VALNValnevaGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$14.00 ➝ $13.008/25/2025VALNValnevaJefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetBuy$14.008/25/2025VALNValnevaHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$18.008/19/2025VALNValnevaHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$18.008/15/2025LRMRLarimar TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetMarket Outperform$22.00 ➝ $18.00(Data available from 9/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookLRMRLarimar TherapeuticsN/AN/AN/AN/A$2.69 per shareN/AONCOOnconetix$2.52M1.97N/AN/A$11.22 per share0.29VALNValneva$196.33M4.79$0.11 per share99.38$2.41 per share4.54VERVVerve Therapeutics$32.33M30.69N/AN/A$5.83 per share1.91Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateLRMRLarimar Therapeutics-$80.60M-$1.56N/AN/AN/AN/A-62.92%-53.98%10/29/2025 (Estimated)ONCOOnconetix-$58.69MN/A0.00∞N/A-3,327.03%-192.74%-89.55%12/8/2025 (Estimated)VALNValneva-$13.25M-$0.98N/AN/AN/A-33.87%-34.78%-13.43%11/6/2025 (Estimated)VERVVerve Therapeutics-$198.71M-$2.11N/AN/AN/A-303.64%-35.81%-27.57%N/ALatest ONCO, VERV, LRMR, and VALN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025LRMRLarimar Therapeutics-$0.47-$0.41+$0.06-$0.41N/AN/A8/14/2025Q2 2025ONCOOnconetixN/A-$4.05N/A-$4.76N/A$0.11 million8/12/2025Q2 2025VALNValneva-$0.27-$0.16+$0.11-$0.16$46.28 million$54.84 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthLRMRLarimar TherapeuticsN/AN/AN/AN/AN/AONCOOnconetixN/AN/AN/AN/AN/AVALNValnevaN/AN/AN/AN/AN/AVERVVerve TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioLRMRLarimar TherapeuticsN/A5.465.46ONCOOnconetixN/A0.070.06VALNValneva0.662.271.77VERVVerve TherapeuticsN/A9.849.84Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipLRMRLarimar Therapeutics91.92%ONCOOnconetix23.89%VALNValneva11.39%VERVVerve Therapeutics97.11%Insider OwnershipCompanyInsider OwnershipLRMRLarimar Therapeutics4.50%ONCOOnconetix3.10%VALNValneva14.91%VERVVerve Therapeutics19.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableLRMRLarimar Therapeutics3082.78 million79.05 millionOptionableONCOOnconetix121.55 million1.50 millionN/AVALNValneva70085.93 million73.12 millionNot OptionableVERVVerve Therapeutics11089.14 million71.94 millionOptionableONCO, VERV, LRMR, and VALN HeadlinesRecent News About These CompaniesWhy Intellia ($NTLA) Just Had A Major BreakoutSeptember 19, 2025 | msn.comEli Lilly's new $5B Virginia facility to target cancer, other illnessesSeptember 17, 2025 | msn.comEli Lilly's new $5B Virginia facility to target cancer, other drugsSeptember 16, 2025 | msn.comHectic Markets, Emotions Lead Biotechs To Tack On CVRsSeptember 10, 2025 | biospace.comBCanaccord Genuity Reaffirms Their Buy Rating on Intellia Therapeutics (NTLA)August 9, 2025 | theglobeandmail.comVerve Therapeutics Announces Merger and Nasdaq DelistingAugust 3, 2025 | theglobeandmail.comGene Therapy Companies Set Sights on Cardiovascular DiseaseAugust 1, 2025 | genengnews.comGVerve Therapeutics (VERV) Reported Results From its Heart-2 Phase 1b Trial for VERVE-102July 29, 2025 | msn.comEli Lilly and Company: Lilly completes acquisition of Verve Therapeutics to advance one-time treatments for people with high cardiovascular riskJuly 26, 2025 | finanznachrichten.deEli Lilly completes acquisition of Verve TherapeuticsJuly 25, 2025 | msn.comLilly completes acquisition of Verve Therapeutics to advance one-time treatments for people with high cardiovascular riskJuly 25, 2025 | prnewswire.comLilly and Verve announce expiration of Verve tender offerJuly 24, 2025 | prnewswire.comPenn CRISPR science is the foundation for a gene-editing heart disease treatment under Eli LillyJuly 24, 2025 | msn.comEli Lilly Advances Pipeline and Gene Focus With Verve AcquisitionJuly 24, 2025 | finance.yahoo.com3 Bullish Biotech Stocks With Explosive Growth Trends...July 21, 2025 | marketbeat.comLilly’s $1 billion CRISPR bet: what Verve means for gene editingJuly 16, 2025 | thepharmaletter.comTGoldman Spotlights These 3 Stocks in Its Bullish S&P 500 Outlook (VERV)...July 15, 2025 | marketbeat.comBiotech Stocks Are Ready to Rebound. Gilead Sciences and 2 More to Watch Now.July 14, 2025 | msn.comBiotech Stocks Are Ready to Rebound. 3 to Watch Now.July 14, 2025 | msn.comTrump Says 200% Pharma Tariffs Are Coming. Wall Street Shrugs.July 13, 2025 | hindustantimes.comHExperimental treatment for high cholesterol edits DNA in the body to reduce LDLJuly 11, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeONCO, VERV, LRMR, and VALN Company DescriptionsLarimar Therapeutics NASDAQ:LRMR$3.38 -1.71 (-33.60%) Closing price 04:00 PM EasternExtended Trading$3.42 +0.04 (+1.04%) As of 06:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.Onconetix NASDAQ:ONCO$3.21 -0.18 (-5.31%) Closing price 04:00 PM EasternExtended Trading$3.23 +0.02 (+0.62%) As of 06:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio.Valneva NASDAQ:VALN$10.95 +1.24 (+12.77%) Closing price 04:00 PM EasternExtended Trading$11.05 +0.10 (+0.91%) As of 05:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is based in Saint-Herblain, France.Verve Therapeutics NASDAQ:VERVVerve Therapeutics, Inc., a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH. It engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 Top-Rated Dividend Growth Stocks to Buy in October Top Insider Buys and Sells From September: Buy, Sell, or Hold? MarketBeat Week in Review – 09/22 - 09/26 Get Exposure to Millennials' Purchasing Power With This ETF Beam Global Gets Buy Rating With 101% Upside Potential Institutional Buying Sets a High Floor for Microsoft Stock High-Momentum ETFs to Mine for Gold, Silver, and Bitcoin ASML Is a Hidden Gem in This Technology Rally, a Catch Up Play Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
